Sai-Hong Ignatius Ou

Title(s)Health Sciences Professor, Medicine
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 01; 12(1):145-151. PMID: 27697581.
      View in: PubMed
    2. Ou SH, Pasi J. Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al. Ann Oncol. 2014 Oct; 25(10):2093. PMID: 25035278.
      View in: PubMed
    3. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012 Sep; 83(3):407-21. PMID: 22257651.
      View in: PubMed
    4. Ou SI, Zell JA. The effect of tumor size on non-size-based descriptors in staging of stage I non-small cell lung cancer. Chest. 2009 Jun; 135(6):1695-1696. PMID: 19497911.
      View in: PubMed